Abstract:Thrombosis, a leading cause of numerous fatalities, particularly in developed nations, accounts for thousands of deaths. The contemporary lifestyle inevitably leads to occurrences of venous thrombosis, including deep vein thrombosis and thromboembolism. This article presents a groundbreaking study where a novel series of N′-(arylmethylidene)-6-( p -methoxyphenyl)-3-methyl-1-phenyl-1 H -pyrazolo[3,4- b ] pyridine-4-carbohydrazide derivatives were efficiently synthesized and screened for thrombolytic activities. Compounds 4a, 4c, 4d , and 4h demonstrated the best antiplatelet activities when using different agonists such as arachidonic acid and collagen. These compounds showed >50 % activity by using agonist collagen and inhibited >50 % platelet aggregation in whole human blood. Compounds 4c and 4d showed the greatest inhibitory effect of 97.98 % and 98.97 %, respectively as compared to other synthesized compounds and aspirin. For platelet aggregation using arachidonic acid, all the synthesized compounds 4a, 4c, 4d and 4h shown >93 % inhibition than that of aspirin. In computational studies, ligands 4c ( ap ) and 4d (ap) exhibited potent interaction with the COX-1 active site, suggesting inhibitory potential against thrombolytic activities. Ligand 4c (ap) scored 8896 and ACE of -418.31 kcal/mol, while 4d (ap) scored 8742 and ACE of -417.43 kcal/mol. Similarly, ligands 4c (ap) and 4h (ap) displayed outstanding docking scores at the COX-2 active site, with 4c (ap ) scoring 8574 (ACE:301.49 kcal/mol) and 4h (ap) scoring 8424 (ACE:276.16 kcal/mol). Synthesized compounds particularly 4c and 4d have the potential to be used for clinical trials and could be beneficial for the designing and development of novel therapeutics for cardiovascular and thromboembolic ailments.

Design and synthesis of potent and selective macrocyclic thrombin inhibitors

Macrocyclic inhibitors targeting the prime site of the fibrinolytic serine protease plasmin

Mechanism-Based Macrocyclic Inhibitors of Serine Proteases

Discovery and Computational Studies of Potent Covalent Kinase Inhibitors with alpha-Substituent Electrophiles Targeting Cysteine

Discovery and Computational Studies of Potent Covalent Kinase Inhibitors with -Substituent Electrophiles Targeting Cysteine

Discovery of a novel series of selective macrocyclic PKCTheta inhibitors

Design, Synthesis and Biological Evaluation of Novel Non-peptide Boronic Acid Derivatives As Proteasome Inhibitors

Design and Synthesis of Novel Macrocyclic Derivatives as Potent and Selective Cyclin-Dependent Kinase 7 Inhibitors

Design, Synthesis, and Biological Evaluation of Novel Phenol Ether Derivatives As Non-Covalent Proteasome Inhibitors.

Synthesis, characterization and thrombolytic activity evaluation of novel pyrazolo[3,4- b ]pyridine-4-carbohydrazide derivatives

Design, synthesis, and structure-activity and structure-pharmacokinetic relationship studies of novel [6,6,5] tricyclic fused oxazolidinones leading to the discovery of a potent, selective, and orally bioavailable FXa inhibitor.

Design and synthesis of novel factor XIa Inhibitors with bicyclic isoquinoline and naphthalene fragments

Novel Thiol-Based Tace Inhibitors: Rational Design, Synthesis, and Sar of Thiol-Containing Aryl Sulfonamides

Exploring 2-Sulfonylpyrimidine Warheads as Acrylamide Surrogates for Targeted Covalent Inhibition: A BTK Story

Back-Pocket Optimization of 2-Aminopyrimidine-Based Macrocycles Leads to Potent EPHA2/GAK Kinase Inhibitors

Synthesis of CC, CN coupled novel substituted dibutyl benzothiazepinone derivatives and evaluation of their thrombin inhibitory activity.

Design and synthesis of a series of novel macrocycle Janus kinase 2 inhibitors

Design, synthesis, and biological evaluation of pyrrolopyrimidine derivatives as novel Bruton's tyrosine kinase (BTK) inhibitors

Structure-aided optimization of non-nucleoside M. tuberculosis thymidylate kinase inhibitors

Thiol-to-amine Cyclization Reaction Enables Screening of Large Libraries of Macrocyclic Compounds and the Generation of Sub-Kilodalton Ligands

Structure-activity Relationship Investigation for Benzonaphthyridinone Derivatives As Novel Potent Bruton's Tyrosine Kinase (BTK) Irreversible Inhibitors.